Lilly’s orforglipron trumps oral semaglutide in head-to-head trial

Eli Lilly's oral GLP-1RA, orforglipron, significantly outperformed Novo Nordisk's oral semaglutide in the head-to-head ACHIEVE-3 Phase III trial, demonstrating superior reductions in A1C (up to 2.2% vs. 1.4%) and greater weight loss (up to 9.2% vs. 5.3%), along with improvements in cardiovascular risk factors. This clinical success positions Lilly to regain market leadership in the oral cardiometabolic treatment arena, intensifying competition with Novo Nordisk in the rapidly growing GLP-1RA market, projected to exceed $125 billion by 2033, with Lilly planning FDA filings for orforglipron in 2026.

Analysis

Eli Lilly (LLY) has secured a significant competitive advantage over Novo Nordisk (NVO) in the oral GLP-1RA market, based on head-to-head Phase III trial data for its candidate, orforglipron. The ACHIEVE-3 trial results demonstrate clear clinical superiority, with high-dose orforglipron achieving a 2.2% A1C reduction and 9.2% weight loss, substantially outperforming oral semaglutide's 1.4% A1C reduction and 5.3% weight loss at its highest dose. Critically, nearly three times as many patients on high-dose orforglipron reached near-normal blood sugar levels (A1C <5.7%) compared to those on high-dose oral semaglutide (37.1% vs. 12.5%). This clinical victory, coupled with improvements in cardiovascular risk factors and a manageable safety profile, strongly positions orforglipron as a best-in-class oral agent. While Novo Nordisk currently leads in subcutaneous GLP-1RA sales ($25bn vs. Lilly's $16.47bn), Lilly's faster growth rate and this decisive trial win signal a potential shift in market leadership. With Lilly planning FDA filings in 2026, this development is a pivotal event in the race to capture share in a market projected to exceed $125 billion by 2033.

Key Decisions for Investors

• Investors should view these Phase III results as a material positive catalyst for Eli Lilly, as orforglipron's demonstrated superiority significantly de-risks its path to market and strengthens its long-term competitive positioning in the lucrative oral cardiometabolic segment.
• Consider the increased competitive pressure on Novo Nordisk; the clear inferiority of oral semaglutide in this head-to-head trial could lead to future market share erosion and pricing challenges once orforglipron launches.
• Monitor Eli Lilly's execution on its planned 2026 FDA submissions for orforglipron, as a timely approval and successful commercial launch are critical to translating this clinical victory into tangible market share gains against Novo Nordisk.